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Abstract.  Intercellular adhesion molecule-1  (ICAM-1) 
on the surface of cultured umbilical vein and 
saphenous vein endothelial cells was upregulated be- 
tween 2.5- and 40-fold by rlL-1,  rTNF, LPS and 
rIFN~/corresponding to up to 5  ×  106 sites/cell. En- 
dothelial cell ICAM-1  was a  single band of 90 kD in 
SDS-PAGE.  Purified endothelial cell ICAM-1  recon- 
stituted into liposomes and bound to plastic was an ex- 
cellent substrate for both JY B lymphoblastoid cell 
and T  lymphoblast adhesion, Adhesion to endothelial 
cell ICAM-1  in planar membranes was blocked com- 
pletely by monoclonal antibodies to lymphocyte func- 
tion associated antigen-1  (LFA-1) or ICAM-I. Adhesion 
to artificial membranes was most sensitive to ICAM-1 
density within the physiological range found on resting 
and stimulated endothelial cells.  Adhesion of JY B 
lymphoblastoid cells, normal and genetically LFA-1 
deficient T  lymphoblasts and resting peripheral blood 
lymphocytes to endothelial cell monolayers was also 
assayed. In summary, LFA-1 dependent (60-90%  of 
total adhesion) and LFA-l-independent basal adhesion 
was observed and the use of both adhesion pathways 
by different interacting cell pairs was increased by 
monokine or lipopolysaccharide stimulation of en- 
dothelial cells. The LFA-l-dependent adhesion could 
be further subdivided into an LFA-1/ICAM-I-depen- 
dent component which was increased by cytokines and 
a  basal LFA-l-dependent, ICAM-l-independent compo- 
nent which did not appear to be affected by cytokines. 
We conclude that ICAM-1  is a  regulated ligand for 
lymphocyte-endothelial cell adhesion, but at least two 
other major adhesion pathways exist. 
I 
NTERCELLULAR  and cell-matrix adhesion are  critical 
during morphogenesis and in the adult organism. Adhe- 
sive interactions are mediated by a diverse array of cell 
surface and matrix molecules which show specialization for 
interactions involving particular cell  types.  Interaction of 
lymphocytes with endothelial cells is important for entry of 
lymphocytes into lymphoid tissues (15, 17, 45) and extravasa- 
tion at sites of immune and inflammatory reactions (45) and 
is an interesting model for studying dynamic cell-cell inter- 
actions. 
Adhesion of lymphocytes to many cell types is inhibited 
by monoclonal antibodies (mAbs)  to lymphocyte function 
associated antigen-I (LFA-1)  ~  (CDll, CDI8) (38, 46). LFA-1 
is a  member of a  family of three leukocyte heterodimers 
which have distinct a subunits of 150-180 kD and a common 
13 subunit of 95 kD (42).  Extracellular matrix receptors are 
also heterodimers; recently their 0t and 13 subunits have been 
1. Abbreviations used in thispaper: FBS, fetal bovine serum; HDF, human 
dermal  fibroblast;  HSVEC,  human  saphenous  vein  endothelial  cell; 
HUVEC, human umbilical vein endothelial cell; ICAM, intercellular adhe- 
sion molecule; IFN, interferon; IL, interleukin; LAD, leukocyte adhesion 
deficiency; LFA, lymphocyte function associated; LPS, lipopolysaccharide; 
PBL,  peripheral blood lymphocyte. 
found to be 25 to 48% homologous to those of LFA-I (22, 
23, 46, Larson, R. and T. A. Springer, manuscript in prepa- 
ration). This relationship suggests that LFA-1 is a member 
of a  super-family of heterodimeric, divalent cation-depen- 
dent adhesion molecules, designated the integrins (22).  How- 
ever,  the LFA-1, Mac-1 and p150,95  antigens are the only 
members of this super-family which are known to be  in- 
volved in cell-cell rather than cell-matrix adhesion. 
We have identified a putative ligand for LFA-1 called inter- 
cellular adhesion molecule-1  (ICAM-1)  (39).  Monoclonal 
antibodies to ICAM-1 inhibit several LFA-1 dependent cell- 
cell interactions including the phorbol ester-stimulated ho- 
motypic adhesion of B-lymphoblastoid cell lines (39) and the 
binding of T  lymphoblasts to fibroblasts (11). ICAM-1  ex- 
pression on dermal fibroblasts and endothelial cells in vitro 
is increased by exposure to interferon 7 (IFN't), interleukin-1 
(IL-1) and tumor necrosis factor (TNF) (11, 35).  Increasing 
ICAM-I on dermal fibroblasts correlates with a significant 
increase in T lymphoblast adhesion which requires the LFA- 
1/ICAM-l-dependent pathway. 
To directly test the potential role of ICAM-1 in lymphocyte 
adhesion to endothelial cells we have examined the adhesion 
of resting or activated T and B lymphocytes to purified en- 
© The Rockefeller University Press, 0021-9525/88/07/32 I/11 $2.00 
The .lournal of Cell Biology, Volume 107, July 1988 321-331  321 dothelial cell ICAM-I reconstituted into planar membranes. 
We have also assayed the adhesion of lymphocytes to resting 
or activated cultured endothelial cells with attention to the 
correlation between ICAM-1  expression and adhesion, and 
the role of LFA-1 and ICAM-1.  Our results show that lym- 
phocyte-cultured endothelial cell adhesion is a complex pro- 
cess using at least three different adhesion pathways, one of 
which is regulated by the cell surface density of ICAM-1 and 
is  mediated by  interaction of LFA-1 on  lymphocytes and 
ICAM-1  on endothelial cells. 
Materials and Methods 
Materials 
Recombinant human interleukin (IL)-II~ expressed in Escherichia coli (2  x 
107 U/rag), rabbit antisera to natural IL-1 (pI 7.0), and recombinant tumor 
necrosis factor  (rTNF)  were a  gift of Dr.  Charles  A.  Dinarello  (Tufts 
University School of Medicine, Boston, MA). Recombinant human TNF 
(1  x  l0  s U/mg) was from Genentech (San Francisco, CA). Recombinant 
human IL-lct (5  x  107 U/mg) was from Dr.  Peter Lomedico (Hoffmann 
La Roche, Nutley,  NJ). Recombinant human interferon (IFN)T  expressed 
in CHO cells (1  x  106 U/rag) was a gift of Dr. D. Novick, (Weizmann In- 
stitute, Rehovot, Israel). Endothelial cell growth supplement was obtained 
from Meloy Labs (Springfield, VA). Fetal bovine serum was obtained from 
Gibco (Grand Island, NY) or Hyclone (Logan, UT). Clinical grade human 
plasma fibronectin was obtained from the New York Blood Research Center 
(New York, NY). Clinical grade Polymyxin B sulfate was purchased from 
Pfizer (New York, NY). Sepharose CL 4B was purchased from Pharmacia 
(Uppsala, Sweden). Iodogen was obtained from Pierce (Rockford, IL). Li- 
popolysaccharide (LPS) (E.  Coil, 0Ill:B4),  heparin, and other reagents 
were obtained from Sigma Chemical Co.  (St.  Louis, MO).  Carrier-free 
Na~2~I and Na2~lCrO4 were purchased from New England Nuclear (Bos- 
ton, MA). 
mAbs 
TS1/22 (LFA-1 mAb, IgG1), TS2/18 (CD2 mAb, IgG1), TS2/9 (LFA-3 mAb, 
IgGl) (41), W6/32 (HLA-A,B mAb, IgG2a) (3) and RRI/I (ICAM-I mAb, 
IgG1) (39) were used as dilutions of hybridoma culture supernatants or as- 
cites, or as purified IgG. R6.5 (ICAM-I mAb, IgG 2a) IgG and lab were 
a gift of Dr. Robert Rothlein (Boehringer Ingelheim, Ridgefield, CT). mAbs 
were purified from culture supernatants by protein A affinity chromatogra- 
phy. F(ab')z fragments of RRI/1 and TS2/9 were prepared by papain cleav- 
age and their purity determined by SDS-PAGE (34). Purified mAb were 
covalently coupled to Sepharose CL-4B after CNBr activation (29). 
Cell Culture.  Human umbilical vein endothelial cells were a gift of Dr. 
Michael A. Gimbrone, Jr. (Brigham and Women's Hospital, Boston, MA) 
a~d human saphenous vein endothelial cells were a gift of Dr. Peter Libby 
(Tufts  University School of Medicine, Boston,  MA).  These cells were 
maintained up to 25  doublings in RPMI  1640  with 20%  FBS (Hyclone, 
[LPS] =  0.025 ng/mi), 5 I-tg/ml bovine endothelial cell growth supplement, 
10 ~tg/ml heparin (porcine), 25 mM Hepes, 5 mM glutamine and 50 p.g/ml 
gentamicin (16, 50). Tissue culture surfaces were treated with 1 p.g/cm  2 hu- 
man plasma fibronectin in Hanks' balanced salt solution (HBSS) for 20 min 
at 37°C to promote endothelial cell attachment. Endothelial cells (2,500) 
were seeded into 96-well plate wells and grew to confluence in 3 d. En- 
dothelial cells were treated with cytokines or LPS in the presence of en- 
dothelial cell growth supplement and heparin and were washed three times 
with complete media before assay.  Dermal fibroblasts were a gift of Dr. 
James Rheinwald (Dana Farber Cancer Institute, Boston, MA) and were 
maintained in RPMI-1640 with 10%  FBS. 
Peripheral blood mononuclear cells were obtained by dextran sedimenta- 
tion and Ficoll-Hypaque (1.077) centrifugation. Lymphocytes were enriched 
by incubating mononuclear cells in RPMI-1640 10% FBS in tissue culture- 
treated plastic petri dishes for 1 h two times and saving the nonadherent 
cells. T  lymphoblasts were prepared by incubating mononuclear cells at 
106 cells/ml with 2  I.tg/ml concanavalin A  (Con A) in RPMI-1640 20% 
FBS for 3 d, washing out the Con A and then culturing for 4-10 d in RPMI- 
1640 20% FBS containing 2.5 ng/ml rlL-2. T lymphoblasts were prepared 
from mononuclear cells of severely affected LAD patients (BBN and ZJO). 
It was particularly important to maintain these cells at high density (1-2  × 
106 cells/ml) and rIL-2 was added during the first 3 d also. The JY B lym- 
phoblastoid cell line was obtained from Dr. Jack Strominger (Dana Farber 
Cancer Institute,  Boston,  MA).  It  was  maintained  in  complete media 
(RPMI-1640,  10%  FBS, 2.5 mM glutamine, 50 p.g/ml gentamycin). 
lmmunofluorescence  Flow Cytometry.  Monodispersed suspensions of 
endothelial cells were prepared by brief trypsinization which was found to 
give the same levels for ICAM-I, HLA-A,B and LFA-3 as EDTA and me- 
chanical dispersal (11). Cells were stained as previously described (11) ex- 
cept that phycoerythrin conjugated goat anti-mouse IgG (Biomeda, Foster 
City, CA) was used instead of  the fluoresceine conjugate. Samples were ana- 
lyzed on a Coulter Epics V flow cytometer (Coulter, Hialeah, FL). 
Analytical Immunoaffinity  Isolation and SDS-PAGE. Endothelial cell 
monolayers (4 x  106 cells) were treated with media, IL-113, TNF or IFNy 
for 24 h. Monolayers were washed three times with 0.15 M NaCI, 0.025% 
NAN3, 25 mM Tris, pH 8 (TSA), and then lysed in 2 ml TSA  +  1% Triton 
X-100,  1 mM phenylmethylsulfonyl fluoride (PMSF),  10 mM iodoaceta- 
mide and 200 mU/ml aprotinin (lysis buffer) per flask for 30 min at 4°C. 
The lysates were centrifuged at 14,000  x  g for 15 min, were incubated over- 
night with 20 p.1 mouse IgG Sepharose CL 4B, and the supernatant reserved. 
One-third of the lysate was incubated with 20 Ixl of mAb Sepharose for 6 h. 
After washing (25)  the mAb-Sepharose, protein was eluted by boiling in 
sample buffer with 50 mM iodoacetamide and electrophoresed (26). 
Purification of ICAM-1 from LPS-Activated HUVEC. The procedure 
was modified from Marlin and Springer (30). Endothelial cell monolayers 
(8  x  107 cells) were treated with  10 lag/ml  LPS for  12-16  h.  The cells 
were lysed in 20 ml of lysis buffer for 30 min at 4°C. The lysate was cen- 
trifuged 1,000 g for 10 rain and this supernatant was centrifuged at 100,000 
g for 1 h. The supernatant was passed over a 1 ml RRl/l-Sepharose CL-4B 
column (1.5 mg/ml lgG) at a  flow rate of 0.1  ml/min. The column was 
washed with 10 vol of 0.t% Triton X-100 in PBS, then 5 vol of 50 mM tri- 
ethylamine, pH 11, 0.1% Triton X-100, 0.15 M NaC1 and finally 5 vol of 1% 
octyl-B-D-glucopyranoside in PBS.  ICAM-1  was eluted with 50 mM tri- 
ethylamine pH 12.4, 1% octyl-I~-D-glucopyranoside,  0.15 M NaCI at a flow 
rate of 0.1 ml/min and fractions were collected in tubes containing 0.1 vol 
of I M Tris, pH 7.5, 1% octyl-13-o-glucopyranoside. ICAM-1 eluted in 1-2 
column vol. 
Reconstitution  of ICAM-1 into Phospholipid Vesicles and Binding to 
Plastic. Egg phosphatidylcholine and cholesterol were combined at a 7:2 
molar ratio in chloroform/methanol (9:1), dried under a stream of nitrogen 
and held under a vacuum for 1 h. The Iipids were solubilized with PBS, 
2%  octyl-13-B-glucopyranoside  at a  lipid concentration of 0.4  raM.  The 
solubilized lipids were combined with 1 vol of neutralized ICAM-1  eluate 
or as a control, glycophorin in the same buffer at molar lipid to protein ratios 
between 1,000:1 and 80,000:1. Vesicles were formed by dialysis against four 
changes of PBS (32). The ICAM-I or glycophorin vesicle suspension (30 
gl/well) was added to 96-well tissue culture treated plates and incubated for 
1 h at 37°C with a moist paper towel draped over the plate to reduce evapora- 
tion (30). The wells were washed five times with 200 ~tl of complete media 
without exposing the bottom of the well to air.  ICAM-1  vesicles bound to 
plastic at a similar efficiency as to glass (5) (not shown) as has also been 
found by Quill and Schwartz (37). 
Radioimmunoassayfor  ICAM-1. Purified RR1/1 was iodinated using io- 
dogen (14) to a specific activity of 10 gCi/gg. Iodinated antibody binding 
to cell monolayers was determined as previously described (11). The specific 
activity of the [~2Sl]RRI/I was adjusted using unlabeled RRI/I  to obtain a 
linear signal over the range of antigen densities encountered in this study. 
Nonspecific binding was determined in the presence of a hundred fold ex- 
cess of unlabeled RRI/1 and was subtracted from total binding to yield the 
specific binding. All points were done in quadruplicate. 
Site-Number Determinations. RRlll was iodinated to a specific activity 
of around 0.5 l~Ci/lag as above. Specific activity was determined using a mo- 
lecular weight of 75,000 assuming bivalent binding. Binding experiments 
were done as above except the [~25I]RR1/I was added at increasing concen- 
trations until saturation was evident. The number of cells was determined 
after trypsinization and counting of cells from four wells for each pretreat- 
merit condition. 
Adhesion Assay. Lymphocytes, T lymphoblasts or lymphoid tumor cells 
were labeled with S~Cr by incubation of cells at 5-50  x  106 cells/ml with 
200-400 ~tCi/ml Na2 5~CrO4 for I-1.5 h at 37"C in complete media. The 
cells were washed four times with complete media (with 25 mM Hepes). 
T lymphoblasts were washed with complete media +  5 mM methyl-a-man- 
noside during the hrst two washes. Plastic-bound vesicles or confluent en- 
dothelial cell monolayers in 96-well plates were treated as described for each 
experiment, mAb and labeled cells were added to a final volume of 100 I.tl. 
In some experiments cells,  plastic-bound vesicles, or  monolayers were 
treated with mAb and then unbound mAb removed by washing before the 
binding assay. The labeled cells were allowed to settle and adhere for 1 h 
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II:5I]ICAM-1  mAb bound (cpm) 
Condition (16 h)  HUVEC  A  HSVEC  A 
Experiment  1 
Control  497  +  14  - 
100 ng/ml rlL-1  13  5,680  +  633  11 x 
50 ng/ml rIL-I  ct  9,910  +  538  20× 
50 ng/rrd rTNF  tt  14,905  -i-  1,324  30x 
10  p.g/ml LPS  9,530  +  512  19x 
10 ng/ml rIFN7  1,306  _+  308  2.6 × 
rIL-ll3  +  rTNF  17,943  +_  1,410  36x 
rlL-113  +  LPS  11,636  _+  761  23× 
rlL-l[3+  rlFN'),  7,849  +  601  16× 
rTNF  +  LPS  21,004  +  1,241  42x 
rTNF  +  rlFNy  20,232  +  1,189  4Ix 
LPS  +  IFN7  14,509  +  320  29x 
Experiment 2 
Control  603  +  11  - 
Polymyxin B  (10 txg/ml)  480  +_  23  0.79x 
Polymyxin B  +  rIL-1  5,390  _+  97  8.9x 
Polymyxin B  +  rTNF  14,801  +_  389  25  x 
1  p.g/rnl  LPS  7,598  +  432  13 × 
Polymyxin B  +  LPS  510  _+  44  0.85x 
1,132  _+  31 
8,320  _+  766  7.3× 
12,690  _+  657  11.2x 
10,459  ___  388  9.2x 
4,002  +__ 664  3.5 x 
HUVEC or HSVEC were seeded into 96 well plates at 1:3 from a confluent monolayer and allowed to grow to confluence. Cells were then treated  with the indicated 
materials or media for 16 h and the RIA done as in Materials and Methods. 
at 37°C.  Nonadherent cells were removed by washing with warm media 
(18).  Wells were examined microscopically before and after washing to de- 
termine the evenness of cell  settling and damage to the endothelial cell 
monolayer during washing. Damage to the monolayer was never significant 
(<5%  area).  Radioactivity  was  quantified  after  solubilization  of  the 
monolayer in 0.I  N  NaOH.  Percent adhesion was calculated as the (Ex- 
perimental counts  -  Counter background)/(Input counts  -  spontaneous 
release). 
Light Microscopy. ICAM-I and LFA-3 were incorporated into Iiposomes 
as above at a lipid:protein ratio of 1,000:1. LFA-3 was purified as previously 
described (12). Membranes were formed on 12-mm glass coverslips (Bellco 
Glass, Inc, Vineland, NJ) in 24 well plate wells (5,  12). T  lymphoblasts 
(106) were added and incubated for 1 h at 37°C and then washed five times 
with warm media. Coverslips with planar membranes and bound cells were 
attached to glass slides using two pieces of two-sided tape spaced 8-ram 
apart without allowing the membrane surface to come into contact with air. 
This could be done by turning the coversl~p membrane side-down with for- 
ceps under media and rapidly transfering the inverted slide with a hanging 
drop of media. Pictures were taken using a Zeiss standard microscope with 
phase contrast optics. 
Results 
ICAM-1 Expression on Cultured Endothelial Cells 
ICAM-1 expression was assayed on human umbilical vein en- 
dothelial cells  (HUVEC)  and human saphenous vein en- 
dothelial cell (HSVEC)  using radioimmunoassay and im- 
munofluorescence flow cytometry. The basal expression of 
ICAM-1 is 2-4-fold higher on HSVEC than on HUVEC, as 
determined both  by  [12~I]ICAM-1 mAb  binding  (Table  I) 
and immunofluorescence  flow cytometry (not shown). In our 
hands HSVEC grew more slowly than HUVEC and this may 
be the basis of the higher ICAM-1 expression on these cells. 
Quiescent fibroblasts express higher levels of ICAM-1 com- 
pared with rapidly dividing cells (11) and HUVEC maintained 
at confluence for several days gave immunofluorescence flow 
cytometry profiles similar to HSVEC. As previously reported 
(35)  exposure of HUVEC to recombinant rlL-la,  rlL-l~, 
and rTNFet increases ICAM-1 expression 10-30-fold (Table 
I). Used at optimal concentrations for this response, rlL-1 a, 
rTNF and LPS were the most potent inducers and rlL-113 was 
less potent.  These results should be interpreted conserva- 
tively since only single recombinant preparations were tested. 
The  absolute number  of ICAM-1  mAb-binding  sites was 
quantified by  saturation binding  with  [~2sI]ICAM-1 mAb 
(Table II). Basal expression of ICAM-1 varied between 5-10 
x  104  sites/cell, but after rTNF stimulation it is a-major 
HUVEC surface component at 3.5  x  106 sites/cell. Combi- 
nations of rTNF and rlFNy, and LPS and rlFN~/at optimal 
concentrations resulted in greater than additive effects  on 
ICAM-1  expression (Table  I).  rlL-113 and rTNF increased 
ICAM-1  expression  half-maximally at  15  ng/ml and  0.5 
ng/ml, respectively (not shown). The results on ICAM-1 in- 
duction were confirmed at the single cell level by immuno- 
fluorescence  flow cytometry (Fig.  1).  Furthermore,  flow 
cytometry showed that ICAM-1  staining on HUVEC  and 
HSVEC (not shown) was heterogeneous showing a normal 
distribution with a half-height width spanning one log. While 
Table II. Site-number Determination for ICAM-1 
HUVEC treatment  Sites/cell  _+  SD 
×10-~ 
Media  1.0  _  0.1 
LPS  31.8  +  1.4 
TNF  35.0  +  2.0 
LPS  +  TNF  54.2  +  2.5 
HUVEC  at  about  1  ×  10' cells/well  were treated  as indicated  for  16 h  at 
37°C.  The concentrations of LPS  was  10  I.tg/ml and TNF  was  10 ng/ml. 
Results are from two experiments. 
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Figure L Immunofluorescence flow cytometry of HUVEC. HUVEC 
were treated  with media (a),  10 ng/ml rlL-113 (b),  10 ng/ml  rTNF 
(c), or 1,000 U/ml rlFNy (d) for 24 h. Monodispersed suspensions 
were prepared by brief trypsinization  which does not affect ICAM-1 
expression.  (dotted line) Nonbinding control. (solid line) ICAM-I. 
some of  this heterogeneity in staining may be due to variation 
in cell size, staining with ICAM-1 mAb was more heteroge- 
neous than with LFA-3 mAb or HLA-A,B mAb (not shown). 
Low  endotoxin  serum  (0.025  ng/mi)  was  used  in  all  of 
these studies and experiments with the LPS neutralizing an- 
tibiotic polymyxin B showed that the endotoxin levels in the 
growth media had little effect on expression of ICAM-1  on 
HUVEC (Table I).  These experiments  further  showed that 
effects of recombinant IL-1 and TNF were not attributable 
to endotoxin contamination. 
IL-1 and TNF caused ICAM-1 expression to be increased 
rapidly between 1 and 8 h and then more slowly over a period 
of  days, as previously described (35). ICAM-1 expression re- 
mained elevated for 7 d in the presence of IL-1 or TNF, but 
returned to basal levels when the mediators were washed out 
(not shown). The time-course of LPS contrasted with that of 
IL-1 or TNF since maximum expression  was seen at  12 h 
(25-fold basal) after which ICAM-1 expression decreased to 
an  intermediate  level by 24 h  (15-fold basal). 
Endothelial  Cell ICAM-1  Biochemistry.  ICAM-1  shows 
significant relative molecular mass (Mr) heterogeneity when 
immunoaftinity  isolated  from  different  cell  types  (11). 
ICAM-1 isolated from HUVEC had an M, of '°90,000 un- 
der nonreducing conditions (Fig. 2 A). IL-1 and TNF treat- 
ment for 24 h resulted in an increase in the amount of isolated 
[CAM-I  corresponding to  the  increase  in ICAM-1  surface 
expression.  However  there  was  no change  in ICAM-1  Mr 
(Fig. 2 A). IFNy treatment resulted in a small increase in im- 
munoprecipitated ICAM-1, but a stronger increase in HLA- 
Figure 2. SDS-PAGE of ICAM-I. 
(a)  HUVEC  were  treated  with 
media (lanes 1-3), I0 ng/ml riL- 
l13  (lanes  4-6),  10  ng/ml  TNF 
(lanes  7-9), and  1,000 U/ml IFN 
¥ (lanes 10-12). Lysates from 4 × 
106 cells  were  prepared  and im- 
munoatfinity  isolation  was  per- 
formed with RRI/1 ICAM-1 mAb 
Sepharose (lanes 1, 4, 7, and 10), 
TS2/9  LFA-3  mAb  Sepharose 
(lanes 2, 5, 8, and//) or W6/32 
HLA-A,B mAb Sepharose  (lanes 
3, 6, 9, and 12). Protein was eluted 
at  100°C with  SDS and then run 
on nonreducing 8%  SDS-PAGE 
and  the  gel  silver  stained.  (b) 
500 I.tg of purified  ICAM-1 from 
HUVEC  stimulated  with  LPS, 
run  on  a  reducing  10%  SDS- 
PAGE and silver  stained  (33). 
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Figure 3. Adhesion of T lymphoblasts (open squares) and JY cells 
(solid squares) to HUVEC  ICAMq  at different densities.  Cell- 
binding percentages are means of quadruplicate determinations. 
Standard deviations did not exceed 10%. Resting (hatched arrow) 
and TNF (solid arrow) -HUVEC equivalents are based on 3.5  × 
106 sites/cell over 0.28 cm  ~. Data shown are representative of 5 ex- 
periments with T lymphoblasts (d7-13) and two with JY. 
A,B (Fig. 2 A). Other bands appeared to be contaminants or 
weakly associated with ICAM-1,  since only the 90,000-Mr 
ICAM-I  band  was  isolated  when  HUVEC  plasma  mem- 
branes were initially solubilized in  1%  N-lauroylsarcosine 
detergent  followed by  addition  of 2%  Triton  X-100  (not 
shown). 
Reconstitution of  Purified Endothelial Cell ICAM-1 
The ability of endothelial cell ICAM-1  to act as a ligand for 
lymphocyte  adhesion  was  directly  tested  using  purified 
HUVEC  ICAM-1  reconstituted into phospholipid vesicles 
and bound to plastic. ICAM-1  was purified from LPS acti- 
vated  HUVEC  by  immunoaffinity  chromatography  using 
conditions established to recover functional ICAM-1  from 
JY cells (30). SDS-PAGE and silver staining confirmed that 
ICAM-I  was the major species (Fig. 2 B). ICAM-I protein 
(90-kD band) isolated under these conditions can be com- 
pletely reabsorbed to anti-ICAM-1-Sepharose demonstrat- 
ing  retention  of the  epitope  recognized  by  RR1/1 after 
purification (not shown). Immunofluorescence light micros- 
copy of ICAM-1 in plastic bound liposomes suggests that the 
bound  liposomes  remained discrete vesicles (not shown). 
Average expression of ICAM-1  by plastic bound liposomes 
was quantified using saturating  ~25I-anti-ICAM-1 and sites 
per square micron were calculated assuming ICAM-1 distri- 
bution over a flat surface. Reconstitution of  ICAM-I at differ- 
ent  lipid:protein  ratios  resulted  in  different  densities  of 
ICAM-1  when bound to plastic (Fig. 3). The range of densi- 
ties covered included the density on confluent unstimulated 
HUVEC (40 sites/~m  2) and TNF-stimulated HUVEC mono- 
layers (1,600  sites/ltm  2) (arrows in Fig.  3) again assuming 
ICAM-1  distribution on a flat surface. 
Adhesion  to  ICAM-I  in  planar  membranes  was  tested 
using the B lymphoblastoid cell line JY and T lymphoblasts. 
JY has been used previously in studies of LFA-1 dependent, 
phorbol ester stimulated, homotypic adhesion (39, 40). Low 
numbers of JY cells per well (<5  x  104) were used such that 
contact between JY cells was minimal and no phorbol esters 
were used such that homotypic aggregation was not observed 
in this study. T lymphoblasts have been used in a previous 
study as a model for activated T lymphocytes (11). Both JY 
and T  lymphoblasts showed efficient adhesion  to purified 
reconstituted ICAM-I which was dependent on ICAM-I den- 
sity (Fig. 3). Adhesion was most sensitive to ICAM-1 density 
in the physiologic range defined by expression on resting and 
TNF-treated endothelial cells (arrows in Fig.  3).  Adhesion 
was completely blocked by ICAM-1  mAb and LFA-I  mAb 
and adhesion was not seen to membranes containing glyco- 
phorin (Table 1]/). LFA-1 mAb inhibited by binding to the T 
lymphoblasts, while ICAM-1  mAb inhibited by binding to 
the reconstituted ICAM-1  (Table III). ICAM-1  purified from 
HUVEC or a B lymphoblastoid cell line, JY, were similar 
in activity at the one density of the JY material tested. In sev- 
eral experiments no adhesion of either cell type was seen be- 
low  a  threshold  value  of  100  sites/~m  2 (Fig.  3  and  not 
shown). 
T and B lymphocytes bound to ICAM-1  in plastic-bound 
vesicles or planar membranes had a distinctive morphology. 
This  was  particularly  striking  relative to  T  lymphoblast 
adhesion to LFA-3  in planar membranes (12).  T  lympho- 
blasts  adhering  to  ICAM-1  were  spread  and  irregular  in 
shape (Fig. 4 a), while T lymphoblasts adhering to LFA-3 
were  mostly  rounded  (Fig.  4  b).  The  morphology of T 
lymphoblasts adhering to ICAM-1  is most similar to that of 
T  lymphoblasts adhering to HUVEC (not shown). 
B Lymphoblastoid CellAdhesion to HUVEC 
Since .it was clear that both JY cells and T  lymphoblasts 
could adhere to  endothelial cell ICAM-1  at physiological 
densities, the ability of ICAM-1  mAb to block adhesion of 
cells to resting and activated HUVEC was tested. Binding of 
JY  cells to HUVEC and human dermal  fibroblast (HDF) 
monolayers was assayed (Table IV). Adhesion of JY to un- 
Table III. Adhesion of T Lymphoblasts to ICAM-1 in Plastic-Bound Vesicles 
mAb pretreatment 
ICAM- 1  LFA- 1 
Membrane  CD2 
composition  None  Cells  Vesicles  Cells  Vesicles  Both 
HUVEC ICAM-1  44  +  1.2  47  +  1.9  0.5  +  0.1  0.2  +  0.1  42  +  2.6  40  +  4.2 
(1,900/~tm  2) 
JY ICAM-I  39  5=  2.3  40  +  3.8  0.8  +  0.3  0.4  +  0.1  36  +  2.4  37  +  2.0 
(1,300/~m  2) 
Glycophorin  0.3  +  0.2  ..... 
ICAM-I was purified  from LPS activated  HUVEC or JY in an identical manner.  Binding of 51Cr-labeled T  lymphoblasts was determined  as in Materials and 
Methods and is expressed as percentage bound  _+  SD. These results are representative of two experiments. 
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Adherent cells (percentage  +  SD) 
HUVEC treatment  HDF treatment 
mAb in assay  None  IL-1  TNF  None  TNF 
Control  4.6  +  1.7  13  +  2.2  20  +  2.8  3.8  +  1.0  13  +  2.8 
ICAM-I  (RRI/1)  3.3  +  0.4  3.7  +  0.5  4.9  +  1.2  1.3  +  0.3  1.1  +  0.4 
LFA-lct  0.7  +  0.2  0.8  +  0.3  1.0  5:0.1  !.7  +  0.2  2.1  +  0.3 
LFA-3  5.9  +  1.1  10  +  1.3  18  ___  2.3  3.8  +  0.5  11  +  2.9 
Confluent monolayers of HUVEC or HDF in 96 well plates were treated for 24 h with 10 ng/ml recombinant IL-10t or TNF as indicated. Binding of 5~Cr-labeled 
JY cells was determined as described in Materials and Methods.  These results are representative of four experiments. 
stimulated HUVEC was inhibited 85 % by LFA-1 mAb and 
28% by ICAM-1 mAb. In contrast, adhesion of JY cells to 
HDF was inhibited 65 % by ICAM-1 mAb and 55 % by LFA-1 
mAb. ICAM-1 mAb F(ab')2 fragments did not increase the 
amount of inhibition for either HUVEC or HDE These ex- 
periments were repeated with the R6.5  ICAM-1  mAb and 
R6.5  Fab fragments which  binds  to a  different epitope on 
ICAM-1  (Marlin,  S.  M.,  personal  communication),  but 
yielded identical results to RR1/1 (not shown). Treatment of 
HUVEC  and  HDF with  IL-1,  TNF or LPS  resulted  in  a 
significant  increase  in  JY  adhesion  (Table  IV  and  not 
shown). This adhesion was inhibited 95 % by LFA-1 mAb and 
75%  by ICAM-1  mAb.  The  adhesion  in  the  presence  of 
ICAM-1 mAb to resting and activated cells was similar for 
both endothelial cells and fibroblasts, suggesting that ICAM- 
1 mAb inhibited the cytokine and LPS stimulated compo- 
nent. Inclusion in the adhesion assay of neutralizing antisera 
to TNF or IL-1, or of polymyxin B at 10 l~g/ml had no effect 
on the efficiency of JY adhesion to HUVEC stimulated with 
TNF, IL-1 and LPS respectively (not shown). Similarly, in- 
clusion of TNF, IL-1 or LPS in the adhesion assay only (1 h) 
did not affect the efficiency of JY binding to cells which re- 
ceived no prior stimulation (not shown); ICAM-1 expression 
does not increase until after 1 h  (11, 3,5). Furthermore, the 
time course of the mediator effects on endothelial adhesive- 
ness paralleled the kinetics of the increase in ICAM-1 expres- 
sion (not shown). 
ICAM-1 is expressed on JY cells as well as HUVEC. To 
determine on which cell ICAM-1 is functionally important, 
Table V. Cellular Site of mAb Blocking 
mAb Pretreatment  Adherent cells 
JY  HUVEC  (%  __+ SE) 
(TNF  24 h) 
-  -  22.9  +  4.5 
ICAM-1  -  24.2  +  3.1 
LFA-lct  -  0.5  +  0.7 
LFA-3  -  21.0  +  2.7 
-  ICAM-I  3.7  ___  1.4 
-  LFA-Iet  22.2  +  1.9 
-  LFA-3  22.4  +  3.1 
HUVEC were grown to confluence in 96 well plates. HUVEC or ~Cr-labeled 
JY cells were pretreated with 50 ~tg/ml  mAb for 30 rain at 24°C and then 
washed four times with media. The cell adhesion assay was then done as in 
Materials and Methods  in the absence of unbound mAb. ICAM-I  mAb was 
RRI/I.  These results are representative of two experiments. 
cells were pretreated with mAb, washed,  and tested in the 
adhesion  assay  (Table  V).  ICAM-1  mAb  pretreatment  of 
TNF activated HUVEC resulted in inhibition equivalent to 
that obtained when ICAM-1 mAb was included in the assay, 
while pretreatment of JY cells with ICAM-1  mAb had no 
effect. LFA-1 mAb inhibited only when JY cells were pre- 
treated which is consistent with the expression of LFA-1 on 
JY only in this system. This result demonstrates that ICAM-1 
mAb inhibits this interaction by binding to HUVEC ICAM-1. 
JY  adhesion  and  125I-anti-ICAM-1  binding  to  HUVEC 
treated with increasing amounts of TNF was studied to deter- 
mine the correlation between adhesion and ICAM-1 expres- 
sion. JY adhesion increased with increasing TNF concentra- 
tion  (Fig.  5  A).  At  all  TNF  concentrations  LFA-1 mAb 
inhibited almost completely, while ICAM-1 mAb inhibited 
partially with the amount of ICAM-1 mAb resistant adhesion 
remaining  constant  (Fig.  5  A).  The  relative  amount  of 
ICAM-1  expression  was  determined  at  each  experimental 
point  with  [l:5I]anti-ICAM-1,  and  was plotted  against  the 
adhesion dependent on ICAM-1 or on LFA-1, which was cal- 
culated by subtracting the adhesion in the presence of ICAM- 
1 mAb or LFA-1 mAb from the adhesion in the presence of 
the non-binding control mAb (Fig. 5 B). When the percent- 
age of adhering JY cells was plotted against ICAM-1 expres- 
sion  a  very strong  positive correlation was  obtained both 
with  LFA-l-dependent  and  ICAM-l-dependent  adhesion. 
While LFA-1 dependent adhesion extrapolates to 5 % at zero 
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Figure 5.  Effect of TNF  treatment  on JY adhesion  and ICAM-1  ex- 
pression.  HUVEC were grown to confluence in 96 well plates and 
were incubated with the indicated concentration of rTNF for 16 h. 
Adhesion of 5~Cr JY cells was measured as described in methods. 
Binding of [~25I]ICAM-I  mAb was determined in parallel. (a) (Open 
squares) control mAb; (open circles) anti-HLA A,B; (solid squares) 
LFA-I mAb; (solid circles) ICAM-I mAb. (b) Adhesion data same 
as in a. (Solid squares) binding inhibitable by LFA-1 mAb; (solid 
circles) binding inhibitable by ICAM-I mAb. Density is approxi- 
mated assuming all ICAM-1 is expressed on an area with the dimen- 
sion of the well (0.28 cm-'). Similar results were obtained in two 
other experiments. 
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Adherent cells (percentage  +  SD) 
HUVEC  HSVEC 
mAb in assay  PBL  Blasts  PBL  Blasts 
Control  IgG  1  22  +  1.2  81  5-  6.2  30  +  3.0  91  +  7.7 
ICAM-1  20  _  1.5  77  +  5,6  28  +  4.5  81  +  9.2 
LFA-1  ot  6  _  0.8  24  ___  1.4  16  +  3.9  49  +  7.8 
LFA-I  [3  4  +  0.2  -  -  - 
LFA-3  25  +  1,3  83  +  7.0  31  +  2.0  92  +  4,9 
CD2  21  +  2.0  80  +  4.1  -  - 
ICAM-I  +  LFA-1ot  6  +  1.6  22  +  1.9  15  5-  2.8  45  5-  6.3 
ICAM-1  +  LFA-3  23  5-  1.4  79  5-  3.1  -  - 
HEC were seeded into 96 well plates at a  1:3 dilution and allowed to grow to a confluent monolayer. 5  x  104 5tCr-labeled PBL were added with the indicated 
mAb (10 pg/ml IgG) and incubated at 37°C for  1 h. The plates were washed as described in Materials and Methods.  ICAM-1  mAb was RR1/I. These results 
are representative of four experiments with HUVEC and two experiments with HSVEC. 
ICAM-1, consistent with the presence of the ICAM-1 inde- 
pendent adhesion, the ICAM-1 dependent adhesion extrapo- 
lates to near zero adhesion at zero ICAM-1 expression (Fig. 
5). Therefore, the relationship between ICAM-1 expression 
and the efficiency of adhesion of JY cells was linear for the 
range of ICAM-1 expression observed on endothelial cells. 
Resting and Activated Lymphocyte Adhesion to HUVEC 
Adhesion of PBL and T lymphoblasts to resting endothelial 
cells was much more efficient than the basal adhesion of JY 
(Table VI). In both cases adhesion was inhibited by 50-80% 
by LFA-1 ct or 13 subunit mAb, as previously reported (19), 
but only 10% or less by ICAM-1 mAb. RR1/1 F(ab')2 frag- 
ments were no more effective than IgG. The R6.5  ICAM-1 
mAb and  Fab  fragments of R6.5  gave identical  results  to 
RR1/1  (not  shown).  The  combination  of LFA-1 mAb and 
ICAM-1 mAb was no more effective than LFA-1 mAb alone. 
The effect of monokine activation of HUVEC on adhesion 
of T  lymphoblasts was determined.  IL-1 and TNF did not 
increase adhesion of normal T  lymphoblasts over the high 
basal level of 80%, which may represent the maximal adhe- 
sion in our assay (Fig. 6). However, inclusion of LFA-1 mAb 
showed that these  cytokines stimulated  an increase  in the 
LFA-l-independent component of adhesion as indicated by a 
dramatic  decrease  in  the  ability of LFA-1 mAb to inhibit 
adhesion. To confirm our findings on LFA-1 dependent and 
independent  components  of adhesion,  LFA-1  deficient  T 
lymphoblasts were used. Lymphocytes from patients with an 
inherited disease, leukocyte adhesion deficiency (LAD), are 
genetically  deficient  in  LFA-1 due  to  a  mutation  in  its  13 
subunit (1, 23).  LFA-1- T  lymphoblasts (line ZJO with less 
than  1%  normal expression) from an LAD patient showed 
greatly  decreased  adhesion  compared  to  LFA-1  ÷  T  lym- 
phoblasts  (Fig.  6).  Adhesion  of  LFA-1-  cells  was  10% 
basally and was increased to 30%  after HUVEC treatment 
with II-1 for 6 h, or to 58%  after HUVEC treatment with 
TNE  While  adhesion  of LFA-1- T  lymphoblasts was  op- 
timal at 6 h after initiation of lymphokine treatment, it had 
not returned to basal levels at 48 h. Similar results were seen 
with short term cultured  LFA-1- EBV transformed B  lym- 
phoblastoid cell lines from LAD patients (not shown), how- 
ever JY, a long term EBV transformed B cell line, has appar- 
ently lost this LFA-l-independent adhesion pathway. ICAM-1 
mAb had no effect on adhesion by LFA-1  ÷ or LFA-1- T lym- 
phoblasts to endothelial cells. Hence, a completely LFA-1 in- 
dependent component of adhesion is present which is stimu- 
lated by monokines and is not blocked by ICAM-1 mAb. 
An ICAM-1 dependent component was detected in PBL 
adhesion  to  stimulated  endothelial  cells  (Table  VII).  As 
noted above, resting PBL have a level of adhesion to unstimu- 
lated endothelial cells which  is higher than for JY B lym- 
phoblastoid cells and lower than for T lymphoblasts. Basal 
adherence of 22% was increased to 36 to 41%  by LPS and 
TNF and to a  lesser extent by IL-113, correlating with the 
effects of these agents on ICAM-1 expression. This increase 
in total adhesion was accompanied both by an increase in the 
ICAM-1  dependent  adhesion,  similarly to  JY  B  lympho- 
blastoid cell binding,  and in LFA-1 independent  adhesion, 
similarly to T lymphoblast adhesion. The composition of ad- 
herent PBL was not determined with respect to T and B lym- 
phocytes  which  make  up  70-75%  and  15-20%  of  PBL 
respectively, with •10%  large granular lymphocytes. Simi- 
larly,  it was not determined whether the blocking effect of 
ICAM-1 mAb in binding of PBL to activated endothelial cells 
was directed against T  cells,  B cells or both. 
Discussion 
We have found  that purified endothelial  cell ICAM-1  is  a 
ligand for lymphocyte adhesion and have tested the ability of 
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Figure 6. Adhesion of LFA-I  ÷ and LFA-1- T lymphoblasts to IL-1 
and TNF treated HUVEC-HUVEC were grown to confluent mono- 
layers in 96 well plates and were treated with 10 ng/ml rIL-1[3 (a) 
or rTNF (b) for the indicated amount of time. Adhesion of 51Cr- 
labeled LFA-I  + (solid lines) or LFA-1- (dashed lines) T lympho- 
blasts was determined in the presence of control mAb (solid  squares), 
ICAM-I mAb (open circles) or LFA-I mAb (open squares). This 
experiment was with ZJO T lymphoblasts; similar results were ob- 
tained with BBN T lymphoblasts. 
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Adherent PBL (percentage  :1: SD) 
mAb 
HUVEC pretreatment  Control  ICAM-1  LFA- let  LFA-3 
None  22.7  +  i.2  19.2  +  2.0  7.8  +  i.1  22.8  +  1.9 
10 ng/ml rlL-ll3  30.1  +  1.3  26.9  +  1.2  14.9  +  0.2  32.7  4-  1.0 
10 ng/ml rTNF  41.2  4-  0.8  33.1  +  1.1  27.7  ___  1.5  40.3  +  1.8 
10  ttg/ml LPS  36.0  +  1.6  28.4  +  0.6  21.2  4-  1.3  37.9  +  3.4 
1 ng/ml rlFN7  26.3  ±  3.4  24.8  4-  1.1  10.0  +  1.3  29.3  4-  0.8 
Confluent HUVEC in 96-well plates were treated as indicated for 30 h. Cell binding assay with ~Cr-labeled PBL was done as in Materials and Methods. ICAM-1 
mAb was RRI/1.  This experiment is representative of three experiments with PBL from different donors. 
ICAM-1  mAb  to  inhibit  the  adhesion  of lymphocytes to 
HUVEC. At least three lymphocyte adhesion pathways were 
found to be used Jn adhesion of three types of lymphocytes 
to endothelial cells (summarized in Fig. 7): (a) an LFA-1 de- 
pendent, ICAM-1 independent basal adhesion which was not 
significantly changed by cytokines or LPS; (b) an LFA-1 and 
ICAM-1  dependent pathway  which  was  weakly  expressed 
basally, but strongly up regulated by monokines and LPS; 
and (c) an LFA-I  independent pathway which also may have 
a  low basal  expression on cultured cells and was also up- 
regulated by monokines and LPS. Pathways 1 and 3 above 
may actually consist of more than one pathway at the molecu- 
lar level. Our findings extend previous studies using LFA-1 
mAb which had defined only LFA-1 dependent basal adhe- 
sion and a monokine stimulated LFA-l-independent pathway 
(6,  18). 
Adhesion of T  lymphoblasts and JY cells to endothelial 
cell ICAM-I in planar membranes shows that LFA-l-depen- 
dent adhesion of both of these cell types is completely in- 
hibited by ICAM-1  mAb when ICAM-1  is the only LFA-1 
ligand available for adhesion. The complex pattern of mAb 
inhibition or lack of inhibition seen for T lymphoblast, PBL 
and JY cell binding to endothelial cells (Fig. 7) may be the 
result  of additional  adhesion  ligands  expressed by  endo- 
thelial cells. In general, if several adhesion pathways avail- 
able to mediate interaction of two cells are capable of allow- 
ing  stable cell adhesion  under a  given set of binding and 
washing conditions, then mAb to any one pathway may be 
Figure 7. Summary of adhesion results. TNF HUVEC data is for 
endothelial cells treated with 10 ng/ml TNF for 24 h. (*) Binding 
of T lymphoblasts may be at saturation for one or two pathways, 
but the other pathways may be functioning, but not required. 
ineffective in reducing the number of cells bound, although 
the pathway blocked by that mAb may be used. This may be 
the case in ICAM-1  mAb ineffectiveness against PBL adhe- 
sion to resting endothelial cells and T lymphoblast adhesion 
to resting or activated endothelial ceils. Detection of ICAM- 
l's relative contribution to these interactions and accurate as- 
sessment of ICAM-I's contribution to systems such as PBL 
adhesion to activated endothelial cells, in which partial inhi- 
bition was detected with ICAM-1 mAb, will require develop- 
ment ofmAb to the other adhesion pathways (both LFA-1 de- 
pendent and independent) or use of different types of assays. 
Adhesion assays which measure the force required for sepa- 
ration of  cells (49) and the use of flow devices which simulate 
conditions in blood vessels (27) should be useful in further 
evaluating  the  role  of the  different adhesion  pathways  in 
lymphocyte-endothelial cell adhesion. 
ICAM-1  is distinct from other endothelial cell antigens in- 
duced or upregulated by cytokines both in its pattern of ex- 
pression (35) and in size. HUVEC ICAM-1 at ~90 kD under 
nonreducing conditions and ,~100 kD under reducing condi- 
tions (48) is of about average size; ICAM-1 on different cells 
ranges  from 80 to  114  kD  nonreduced,  the heterogeneity 
arising  from N-glycosylation (11, and our unpublished re- 
suits).  ICAM-1  is clearly distinct from the endothelial cell 
antigen E-LAM I, which is involved in HL-60 myelo-mono- 
cytic cell and granulocyte adhesion, by expression pattern 
and  size  in  SDS-PAGE  (4).  ICAM-1  structure  based  on 
cDNA sequencing (44, 48) is in excellent agreement with 
the biochemical data on ICAM-I (11) and further show that 
ICAM-1 from endothelial cells and the HL-60 myelo-mono- 
cytic cell line are identical. ICAM-I is a member of the im- 
munoglobulin  super-family based  on  sequence  homology 
(44, 48). 
ICAM-1  purified from endothelial cells and reconstituted 
into artificial vesicles mediated efficient adhesion of  JY cells 
and T lymphoblasts which was LFA-I  dependent. The rela- 
tionship between percent JY cell or T lymphoblast adhesion 
and ICAM-1  expression in the reconstituted system showed 
a  threshold  for adhesion at  low ICAM-1  density, a  linear 
phase  over the  range  of densities  found  on  cultured  en- 
dothelial cells, and approach to a plateau at higher ICAM-1 
densities. The activity of isolated ICAM-1  in plastic bound 
vesicles was very similar to the activity of ICAM-1  on the 
surface of HUVEC for JY binding. When the ICAM-1  inde- 
pendent adhesion pathway for JY adhesion to HUVEC was 
subtracted out there was a  linear relationship between per- 
cent adhesion and ICAM-1  expression level which is very 
similar to the relationship seen for ICAM-1  in plastic bound 
vesicles. The finding that ICAM-1  in an inert substrate  is 
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HUVEC may not have an active role in LFA-1 dependent 
adhesion. This has been suggested previously since periph- 
eral blood T lymphocytes adhere to glutaraldehyde fixed cul- 
tured HUVEC no less efficiently than to live HUVEC (19). 
Factors such as surface charge density and protein lateral 
mobility may differ significantly between the HUVEC and 
in plastic bound vesicles and these parameters will be useful 
in further interpreting these results when they are measured 
and their influence is systematically studied. 
The proposal of other LFA-1 ligands besides ICAM-1  is 
consistent with prior observation that some cell lines show 
LFA-l-dependent  phorbol  ester  stimulated  aggregation 
which is not inhibited by ICAM-1 mAb (39) and that ICAM-1 
mAb inhibits LFA-1 dependent CTL mediated lysis of only 
a subset of targets (28). Two ICAM-1  mAb which recognize 
different epitopes gave identical results, and we have ruled 
out  the  involvement of Fc  receptors and  antibody cross- 
bridging using appropriate fragments of IgG, so the failure 
to see inhibition of lymphocyte adhesion to HUVEC equiva- 
lent to that given by LFA-1 mAb is a strong negative result. 
The adhesion to endothelial cells which is blocked by LFA-1 
mAb,  but not by ICAM-1  mAb appears not to be due to 
differences in the efficiency of these mAb in blocking adhe- 
sion, since ICAM-1  mAb and LFA-1 mAb are equally effec- 
tive in blocking adhesion to ICAM-1  in planar membranes, 
to dermal fibroblasts (11 and this report), and to epidermal 
keratinocytes (13). 
Lymphocytes adhere  efficiently to  cultured  endothelial 
cells, but not to the endothelial surface of sections of large 
veins and arteries (9,  10).  The same level of lymphocyte 
adhesion, including the presence of a monokine inducible, 
LFA-I independent pathway, is also seen for cultured micro- 
vascular endothelial cells (20), so the phenomenon described 
here and previously (18) is not peculiar to large vessel en- 
dothelial cells. Cultured endothelial cells appear to be in an 
intermediate  state  of activation  in  which  endothelial  cell 
adhesiveness  for  lymphocytes  is  significantly  enhanced, 
but other indications of endothelial cell activation such as 
ELAM-1 are not expressed (4, 35). Endothelial cells in intact 
vessels may be less intrinsically adhesive for lymphocytes 
than cultured endothelial cells. ICAM-1 upregulation may be 
important  in  regulating  lymphocyte interaction  with  en- 
dothelial cells at the site of inflammation. ICAM-1 upregula- 
tion has been observed in inflammation in vivo (8). Based 
on the planar membrane experiments it is clear that HUVEC 
ICAM-1 can be used as a ligand for T lymphoblast adhesion. 
The use of ICAM-1 as a ligand by other leukocytes which ex- 
press significant levels of LFA-1 (24), such as monocytes and 
granulocytes remains to be assessed. 
We used lymphocytes from genetically LFA-1 deficient in- 
dividuals with leukocyte adhesion deficiency (LAD) (1) and 
showed their T lymphoblasts are totally deficient in the LFA- 
1-dependent adhesion pathways,  but demonstrate the LFA- 
l-independent inducible adhesion. These defects correlated 
with the impaired primary responses to specific antigen in 
vitro, and with near normal secondary responses. In vivo, 
defects in lymphocyte function in  LAD are less dramatic 
than those in granulocyte function (1). The ability of LFA-1- 
lymphocytes to extravasate at sites of inflammation is consis- 
tent with the presence of the LFA-l-independent pathway, but 
does not rule out a role for LFA-1 since insufficient data is 
available to detect a relative deficiency. Use of animal models 
for leukocyte-endothelial interactions using LFA-1, ICAM-1 
and  other antibodies  in  vivo is  the only practical way to 
directly assess the physiological role of these molecules (2). 
We and others (18, 31) have been unable to demonstrate 
adhesion of PBL (70-80 % T cells), T lymphoblasts or cyto- 
lytic T cell lines to endothelial cells which can be blocked 
by CD2 mAb or LFA-3 mAb, which partially block the inter- 
actions of cytolytic T lymphocytes and some target cells (24, 
43), and of thymocytes and thymic epithelial cells (51). The 
expression of LFA-3 on HUVEC is only 15 % of that on the 
JY cell line which forms CD2/LFA-3 dependent conjugates 
with cytolytic T lymphocytes and this relatively low expres- 
sion may partially explain the failure to detect the activity of 
this adhesion pathway (our unpublished observations). It is 
also possible that the LFA-3 on endothelial cells has a low 
affinity for CD2. Our results and those of others (18, 31) ap- 
pear to be in conflict with earlier reports that killing of en- 
dothelial cells by cytolytic T lymphocyte/natural killer lines 
was inhibited partially by CD2 mAb and LFA-3 mAb (7). 
This difference could be resolved if the CD2/LFA-3 interac- 
tion in this system was not important for adhesion, but for 
some other process required for cytolysis. Heterogeneity in 
the ability of LFA-3 expressing cells to bind to thymocytes 
or T lymphocytes via the CD2/LFA-3 adhesion pathway has 
been observed in other sytems (51). Our results are in agree- 
ment with the finding of Collins et al.  (7) that LFA-1 mAb 
could partially block killing of endothelial cells. 
This study reveals some interesting parallels between the 
function of LFA-1 and several extracellular matrix receptors, 
which are members of the integrin superfamily. First,  the 
density of reconstituted ICAM-1  required to obtain efficient 
adhesion of 25-40% of input cells is very similar to the sur- 
face density of fibronectin required to allow spreading of 
fibroblastoid cells:  on the order of 103-104 sites/Ixm 2 (21). 
Second, cells adhering to ICAM-1 bearing substrates have a 
distinctive morphology which  includes  cell  spreading.  In 
contrast, T lymphoblasts adherent to LFA-3 bearing planar 
membranes were more refractile by phase-contrast micro- 
scopy indicating a lower degree of spreading. Third, binding 
of multiple ligands, as suggested for LFA-1 here and earlier, 
is a property of some of the integrin family receptors, such 
as platelet glycoprotein IIblIIa which binds to fibrinogen, 
fibronectin, vitronectin, von Willebrandt factor and proba- 
bly thrombospondin (36).  However, unlike receptor-ligand 
binding by many members of the integrin family, binding of 
T lymphoblasts to ICAM-1  in planar membranes is not in- 
hibited by the hexapeptide GRGDSP (30) and ICAM-I con- 
tains no RGD sequences (48). 
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